drugset / Trial / NCT05519111
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
Phase 2
Recruiting
60 enrolled
Icahn School of Medicine at Mount Sinai
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Timeline
- Start
- 2025-04-03
- Primary completion
- 2027-04-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dronabinol | Other / unclassified | 2.5 mg | Oral |
| Subject | Dronabinol | Other / unclassified | 10 mg | Oral |